

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > For curative treatment

EMLc

ATC codes: P01BA01

Indication	Malaria due to Plasmodium vivax <span style="border: 1px solid #ccc; padding: 2px;">ICD11 code: 1F81</span>
INN	Chloroquine
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Additional notes	For use only for the treatment of P. vivax infection
Formulations	Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate) Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 1982 ( <a href="#">TRS 685</a> ) Changed in 1995 ( <a href="#">TRS 867</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Chloroquine</a> 
DrugBank	<a href="#">Chloroquine</a> 

#### Summary of evidence and Expert Committee recommendations

Chloroquine was added to the core list of the EMLc for the treatment of malaria due to Plasmodium vivax.

